Form 4: Teleflex Inc. Executive James Winters Reports Stock Option Grant and RSU Award

James Winters, a Corporate VP at Teleflex Inc., reports the acquisition of stock options and restricted stock units (RSUs) in a recent SEC filing.

Summary

• James Winters, a Corporate VP at Teleflex Inc., filed a Form 4 with the SEC.
• The filing reports the grant of a Stock Option (Right to Buy) for 1,676 shares at an exercise price of $202.09, exercisable in three tranches starting 06/18/2025.
• Winters also received a Restricted Stock Unit (RSU) award for 243 shares, which vests 100% on 06/18/2027.
• Following these transactions, Winters directly owns 1,676 derivative securities and 3,638 shares of common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard executive compensation practices, indicating confidence in the company's future performance.

Positives

• The grant of stock options and RSUs aligns the executive's interests with those of the shareholders.
• The vesting schedule of the stock options and RSUs encourages long-term commitment from the executive.

Industry Context

Stock option and RSU grants are common practices in executive compensation packages to incentivize performance and align management's interests with shareholders in the medical device industry.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives at comparable medical device companies such as Medtronic, Stryker, and Boston Scientific.
• The vesting schedules for the options and RSUs are typical, often spanning three to four years to encourage long-term commitment.

Stakeholder Impact

• Shareholders may view the stock option and RSU grants positively, as they incentivize management to improve company performance.
• Employees may see this as a positive sign of the company investing in its leadership.

Key Dates